AACR Presentations Highlight Preclinical Efficacy of Imipridones in Molecularly-Selected Tumors

Philadelphia, PA (May 19, 2020) – Oncoceutics, Inc. announced that the latest research findings with ONC201 and its novel class of imipridones will be presented at the 2020 annual meeting of the American Association of Cancer Research (AACR) on June 22-24, 2020.
 
The research presented at AACR highlights the antitumor and cancer prevention activity of ONC201 in tumor types with dysregulation of its two binding targets DRD2 and ClpP: H3 K27M-mutant diffuse midline glioma, endometrial cancer, medullary thyroid cancer, small cell lung cancer, and colon cancer. The presentations further highlight novel ONC201 biomarkers that help to further inform the clinical efficacy profile of ONC201 and newly discovered synergistic combinations of ONC201 with chemotherapies and several targeted therapies that suggest new approaches to treat patients with advanced cancers.
 
Additional research features the preclinical efficacy of ONC206 and ONC212 as single agents and in combination in a broad set of tumor types, including endometrial cancer, brain tumors and pancreatic cancer. Research led by Varun Prabhu, Vice President R&D at Oncoceutics, and several collaborators summarize the unique mechanism of action of ONC206, which will be featured in an oral presentation on June 24.
 
Please see below for a complete list of AACR presentations:
 
ONC201 Chemoprevention
14. TRAIL-Inducing Small Molecule ONC201 Prevents Intestinal Tumors in FAP Mouse Model.
June 22, 2020, 9:00AM
 
ONC201 Combinatorial Activity:
1836. ONC201 Shows Synergistic Effect with the Androgen Receptor (AR) Inhibitor Darotulamide in Prostate Cancer Model.
June 22, 2020, 9:00AM
 
4808. ONC201 Decreases Protein Chaperone ClpX to Unleash Mitochondrial Protease ClpP Activity, Integrated Stress Response and Tumor Cell Death.
June 22, 2020, 9:00AM
 
3012. Novel Small Molecule ONC201 Induces Apoptosis in Gastric Adenocarcinoma and Exhibits Synergy with rhTRAIL.
June 22, 2020, 9:00AM
 
5407. Novel Imipridone Combination Therapies Targeting Oncohistone H3 K27M-Mutant Diffuse Midline Glioma (DMG).
June 22, 2020, 9:00AM
 
4042. Potent Synergistic Tumor Cell Suppression from Combination of ONC201 and Epigenetic Modulators EZH2 or HDAC Inhibitors Provides a Novel Treatment Strategy for Solid Tumors.
June 22, 2020, 9:00AM
 
3902. Novel Therapeutic Targeting of Epigenetic Aberrations in Pediatric Sarcomas through Combination of ONC201 and HDAC Inhibitors.
June 22, 2020, 9:00AM
 
5260. Preclinical Studies with ONC201 in Combination with Clinically Approved Chemotherapy as a Novel Treatment Strategy Against Small Cell Lung Cancer (SCLC).
June 22, 2020, 9:00AM
 
3904. The Novel Combination of PAC-1 and ONC201 Circumvent H3K27M-Driven Pro-Survival Gene Expression to Induce DIPG Cell Death.
June 22, 2020, 9:00AM

ONC201 Clinical Translation:
TBD Immuno-modulatory Activity of Selective DRD2 Antagonist ONC201, an Imipridone, in Metastatic Endometrial Cancer (mEC).
Date and time TBD

ONC201 Mechanism and Biomarkers:
3173. Predictive Biomarker Evaluation for the Anti-Cancer Imipridone ONC201.
June 22, 2020, 9:00AM.
 
4794. Mitochondrial Matrix Protease ClpP Agonists Inhibit Cell Growth and Cancer Stem Cell Function in Breast Cancer Cells.
June 22, 2020, 9:00AM
 
ONC206
5688. IND-Enabling Characterization of ONC206 as the Next Bitopic DRD2 Antagonist for Neuro-oncology.
June 24, 2020, 9:00AM
 
5314. A Novel Dopamine Receptor D2 Antagonist (ONC206) Potentiates the Effects of Olaparib in Endometrial Cancer Cells through Inhibition of Cell Proliferation and Modulation of the mTOR Pathway.
June 22, 2020, 9:00AM
 
3797. Investigating the Anti-Cancer Effects of Novel Dopamine Receptor D2 Antagonists in a Panel of Human Cancer Cell Lines.
June 22, 2020, 9:00AM
 
5321. Novel Imipridone ONC206 Inhibits Cell Proliferation and Induces Apoptosis in Uterine Serous Cancer through Altering MAPK/AKT Signaling Network and Metabolic Reprogramming
June 22, 2020, 9:00AM
 
5336. Olaparib Potentiates the Anti-Proliferative and Anti-Metastatic Effects of ONC206 in Ovarian Cancer Cells.
June 22, 2020, 9:00AM
 
2958. ONC206, an Imipridone Derivative, Induces Cell Death through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro.
June 22, 2020, 9:00AM
 
ONC212
6225. Addition of TRAIL Receptor Antagonists after Treatment with ONC201 or ONC212 Converts Pancreatic Cancer Cells from Anti-Proliferative to Apoptotic In Vitro.
June 22, 2020, 9:00AM
 
612. ONC212 Affects ClpXP Complex, Impairs Mitochondrial Bioenergetics and Synergizes with Glycolysis Inhibition in Pancreatic Cancer.
June 22, 2020, 9:00AM
 
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds called imipridones that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist and ClpP agonist. The company is supported by grants from NCI, FDA, The Musella Foundation, and the National Brain Tumor Society, and a series of private and public partnerships.
 
Visit Oncoceutics for more information.